September 17, 2020

 

VIA EDGAR

 

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

 

	Re:	AzurRx BioPharma, Inc.
		Registration Statement on Form S-3 (File No. 333-240129)
		Filed on July 27, 2020

 

Ladies and Gentlemen:

 

In accordance with Rule 461 under the Securities Act of 1933, as amended, AzurRx BioPharma, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission (the “Commission”) at 9:00 a.m., Eastern Standard Time, on September 21, 2020, or as soon as practicable thereafter.

 

Please call James O’Grady of Lowenstein Sandler LLP at (646) 414-6849 to confirm the effectiveness of the Registration Statement or with any questions.

 

 

		Very truly yours,
		AZURRX BIOPHARMA, INC.
		By:        /s/ James Sapirstein
		Name:   James Sapirstein
		Title:     President and Chief Executive Officer